AstraZeneca Pharmaceuticals responds to the chronic obstructive pulmonary disease crisis with the launch of a non-interventional study – COPVAR

Claudia Naidu


According to World Health Organization (WHO) reports, chronic
obstructive pulmonary disease (COPD) is the third-leading cause of
deaths worldwide.[1] Further, it is the sixth-leading cause of disabilityadjusted
life years (DALYs) in middle-income countries – a figure that
is expected to change to the fifth-leading cause worldwide in 2030 – and
the significance of the disease is becoming quite evident. In response to
this, AstraZeneca, a global, research-based biopharmaceutical company
with a vested interest in the development of life-changing respiratory
medications, has launched a cross-sectional study of patients with
severe COPD that assesses patient perception of symptom variability
in Middle East and African (MEA) countries.

Full Text:




  • There are currently no refbacks.

African Journal of Thoracic and Critical Care Medicine| Online ISSN: 2304-0017 | © 2014 Health & Medical Publishing Group 

This journal is protected by a Creative Commons Attribution - NonCommercial Works License (CC BY-NC 4.0) | Read our privacy policy.

Our Journals: South African Medical Journal | African Journal of Health Professions Education | South African Journal of Bioethics and Law | South African Journal of Child Health | Southern African Journal of Critical Care | South African Respiratory Journal South African Journal of Obstetrics and Gynaecology |